Rapport Insider Sells $17.2 Million as Stock Surges 230% in a Year and Phase 3 Trials Near
This Boston-based biotech innovator in CNS disorders just reported significant insider selling amid a year of standout stock gains.
ORIGINAL SOURCE →via Motley Fool
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · US
- [CONFLICT] Eşi için söylenenler Trump'ı sinirlendirdi: Derhal kovulmalı
- [FINANCE] FED faiz kararı ne zaman açıklanacak? Nisan ayı FED faiz beklentisi ne yönde?
- [SPORTS] Ex-Bama DT pleads guilty after posing as NFLers
- [CONFLICT] Brooklyn hassidic Jew found dead in remote area of Colombia, ZAKA working to repatriate body
- [DIPLOMACY] ‘Looming’ risk of nuclear arms race, UN proliferation meeting hears
- [HEALTH] Good cumulative cardiovascular health during young mid-adulthood associated with delayed cardiovascular disease, death